Inhibrx Biosciences Inc. (NASDAQ: INBX) is a Healthcare company (Biotechnology) with a market capitalization of $1.1B. The Maz Rating grades it against the other companies in its sector.
Inhibrx Biosciences Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $74.18, Inhibrx Biosciences Inc. trades at 542.8x sales. Over the last twelve months it generated about $2M of revenue and a net loss of $134M. It runs a gross margin of 19.3%, an operating margin of -6286.7% and a net margin of -7082.9%. It shows return on equity of 373.0%, return on invested capital of -64.3% and a free cash flow yield of -12.2%. On the balance sheet: a debt-to-equity ratio of -3.28 and a current ratio of 7.58. Over the past 52 weeks the share price ranged from $57.30 to $155.29, with a beta of 4.04.
Inhibrx Biosciences Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 3 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.